What we set out to do, and what we’ve continued working on, is exploring all the ways we could create the best possible ...

In the analyses presented at EASL, 24 weeks of treatment with pemvidutide ... “This analysis of patients from our study of pemvidutide in MASLD further reinforces our excitement around the ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

today announced that the Company will present analyses of pemvidutide-treated subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) utilizing the MASH Resolution Index ...

(Journal of Hepatology) EASL also released new guidance on extrahepatic ... Metabolic dysfunction-associated steatotic liver disease (MASLD) in young adults was linked with a greater risk of ...

For the EASL, US Panel, Asian–Pacific Panel, and AASLD guidelines, the addition of albumin and platelets increased the percentage of patients treated by 6.2%, 8.7%, 12.5%, and 11.3% ...

As previously presented at AASLD’s The Liver Meeting in 2024 ... New data being presented at the EASL congress will demonstrate substantial, dose-dependent reductions in liver fat were observed ...

1. What does MASLD mean and why has this replaced the previous name of NAFLD? MASLD stands for metabolic dysfunction-associated steatotic liver disease. MASLD was previously called non-alcoholic fatty ...

Pregnant women with metabolic dysfunction-associated steatotic liver disease (MASLD) face a more than threefold increased risk of preterm birth, according to a new population-based study conducted by ...